Tasmania Updates Medicines Rules and Issues Safety Warning on Unapproved Peptides

Tasmania Updates Medicines Rules and Issues Safety Warning on Unapproved Peptides

16 Nov 2026

The latest Pharmaceutical Services Branch bulletin also highlights a shortage of tapentadol tablets and provides guidance for health professionals managing medicine supply issues.

Changes to Tasmania's Poisons Regulations

Changes to the Poisons Regulations 2018 came into effect on 7 October 2026. The amendments cover several areas of healthcare practice, including:

  • Updating the term 'podiatric surgeon' to 'surgical podiatrist'.
  • Clarifying the rules for endorsed midwives administering narcotic medicines to patients.
  • Authorising dental hygienists to administer certain medicines, including local anaesthetics and topical fluoride, as part of dental treatment.
  • Introducing minor changes to legislation.

Further details are available on the Tasmanian Legislation website.

New Medicines Rules for Endorsed Midwives

A new order, the Poisons (Midwifery Substances) Order 2026, was published on 7 October 2026. It replaces the previous list of specific medicines with broader categories covering Schedule 4 and Schedule 8 medicines.

Under the updated rules, endorsed midwives in Tasmania can prescribe or administer any Schedule 4 medicine and administer any Schedule 8 medicine when clinically needed and within their scope of practice.

However, endorsed midwives are still not authorised to prescribe Schedule 8 medicines in Tasmania.

The changes aim to bring medicines regulations in line with modern midwifery practice and support timely, woman-centred care across maternity services.

Midwives must continue to follow the Nursing and Midwifery Board of Australia (NMBA) requirements, relevant clinical guidelines and workplace policies when prescribing or administering medicines.

They must also check TasScript before prescribing a monitored medicine. Other requirements include following the rules for administering Schedule 8 medicines and prescribing Schedule 4 Declared Restricted substances.

More information is available in the Poisons (Midwifery Substances) Order 2026.

Health Professionals Warned About Unapproved Peptide Products

Health professionals across Australia are being urged to watch for the growing use of unapproved peptide products.

These products are often promoted online and through social media, fitness and wellness networks. They are marketed for weight loss, muscle growth, injury recovery, improved performance and anti-ageing.

However, unapproved peptide products have not been assessed by the Therapeutic Goods Administration (TGA) for safety, quality or effectiveness. They may contain incorrect ingredients, harmful contaminants, inconsistent amounts of substances or none of the advertised ingredients.

Recent TGA testing found that some peptide products did not contain the ingredients listed on their labels.

Health authorities have also reported serious health problems linked to these products. Reported cases include severe vomiting, infections at injection sites, acute pancreatitis and liver injury. Queensland and Victorian health authorities have also reported cases of acute liver toxicity linked to products labelled as retatrutide.

Products of concern include:

  • BPC-157
  • TB-500
  • CJC-1295
  • Melanotan products
  • Retatrutide
  • Products sold as semaglutide or tirzepatide outside approved supply channels.

These warnings do not apply to approved medicines supplied through Australian pharmacies.

Health professionals should consider possible peptide use when patients present with unexplained reactions, injection-site infections, liver problems, pancreatitis or other signs of toxicity. They should also ask about products purchased online, through social media or from overseas suppliers.

A respectful and non-judgemental approach can help patients feel comfortable sharing information about substances they have used.

If harm from an unapproved peptide product is suspected, practitioners should keep the product and its packaging where possible and safe. They should record available details about the product and where it was purchased.

Suspected adverse events and product concerns can be reported to the TGA at RCBReport@tga.gov.au. Reports are useful even when some information is missing or the cause of harm is not confirmed.

Further details are available on the TGA peptide products webpage and its safety alert.

Tapentadol Shortage Raises Concerns About Medicine Supply

A shortage of Palexia® (tapentadol) 50 mg immediate-release tablets has been reported by wholesalers and pharmacies and confirmed by the TGA.

The TGA monitors medicine shortages across Australia and provides information about supply problems and possible ways to manage them through its Medicine Shortage Reports Database.

Health professionals are reminded to take extra care when managing shortages of Schedule 8 medicines to maintain patient care and meet legal requirements.

The Pharmaceutical Services Branch has provided the following advice:

  • If a patient has a section 59E authority and their treatment needs to change urgently because of a shortage, the prescriber can contact the Pharmaceutical Services Branch on (03) 6166 0400 to request verbal approval for a short-term alternative treatment arrangement.
  • Pharmacists do not need to check whether a section 59E authority is in place when dispensing a Schedule 8 medicine.
  • Pharmacists can securely transfer repeat prescriptions for Schedule 8 medicines to another pharmacy. Any important clinical or patient safety information should also be shared.
  • TasScript provides real-time prescribing and dispensing information to help health professionals make safer decisions about monitored medicines.
  • TasScript may issue alerts about monitored medicines, but these alerts do not decide whether a medicine should be prescribed or supplied. Practitioners must consider the patient's circumstances and clinical needs when reviewing an alert, particularly when a shortage has led to a change in prescriber, pharmacy or medicine.

Health professionals can find further information about current medicine shortages on the TGA medicine shortages webpage.

Tasmania Updates Medicines and Poisons Information

The Pharmaceutical Services Branch has also published updated information to help health professionals and the public understand medicines regulations and recent changes.

The latest resources include: